MedTrace Logo

The Effects of Bifidobacterium Breve Bif195 for Diarrhea-predominant Irritable Bowel Syndrome

NCT04808271 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 61

Last updated 2023-07-06

No results posted yet for this study

Summary

The purpose of this study is to investigate if the probiotic Bifidobacterium breve Bif195 (Bif195) will result in improvement in clinical outcome in patients with diarrhea-predominant irritable bowel syndrome (IBS).

Conditions

  • Irritable Bowel Syndrome

Interventions

DIETARY_SUPPLEMENT

Bifidobacterium breve Bif195

1 capsule daily for 8 weeks

DIETARY_SUPPLEMENT

Placebo

1 capsule daily for 8 weeks

Sponsors & Collaborators

  • Chr Hansen

    collaborator INDUSTRY

  • Hvidovre University Hospital

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-04-16
Primary Completion
2023-05-09
Completion
2023-05-09

Countries

  • Denmark

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04808271 on ClinicalTrials.gov